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The purpose of this study was to detect the physiological process of FDG’s ﬁltration from blood to urine and to establish a math-
ematical model to describe the process. Dynamic positron emission tomography scan for FDG was performed on seven normal
volunteers. The ﬁltration process in kidney can be seen in the sequential images of each study. Variational distribution of FDG in
kidney can be detected in dynamic data. According to the structure and function, kidney is divided into parenchyma and pelvis.
A unidirectional three-compartment model is proposed to describe the renal function in FDG excretion. The time-activity curves
that were picked up from the parenchyma, pelvis, and abdominal aorta were used to estimate the parameter of the model. The
output of the model has ﬁtted well with the original curve from dynamic data.
Copyright © 2007 Huiting Qiao et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
The development of positron emission tomography (PET)
has made it possible to detect the physiological process in
a human body. [18F]ﬂuoro-2-deoxy-D-glucose(FDG) is the
analog of glucose, which is widely used in clinical PET exper-
iment [1]. In order to understand the metabolism of glucose
and to detect diseases better, mathematical models of FDG
have been established for brain, heart, liver, and some other
organs [2–5]. Although kidney is the most important organ
in the metabolism system of a human, and large quantity of
FDG in the body is accumulated in the urine through the
kidney [6], yet little work has been done for kidney mod-
elling with FDG PET. There are two major reasons why only
a few mathematical models are established for kidney. The
ﬁrst reason is because of the complicated structure and func-
tion of the kidney [7], and the second reason is due to the
highexcretionofFDGthroughthekidney[6,8].FDG,unlike
glucose, cannot be reabsorbed in the proximal tubules of the
kidney, and so FDG will be accumulated in the urine.
To describe the ﬁltration process of FDG from blood to
urine, seven normal volunteers took part in the dynamic
FDG-PET experiment. The imaging data has been used for
kinetic analysis and parameter estimation.
Compared to the high concentration of FDG in kidney
collection system, the small quantity of metabolized FDG in
kidney can be neglected. The dynamic imaging shows the ﬁl-
tration of FDG and the process of urinary excretion. Though
three-compartment four-rate model is widely used to de-
scribe the metabolism of some of the human organs, it is
notsuitablefordescribingkidney.Aunidirectionalcompart-
ment model is proposed to show the transport process of
FDG from blood to urine. Due to the kidney which con-
tains great quantity of blood vessel and collection system of
urine, the eﬀect fractions from the blood and the urine to
parenchyma will be all considered in the model.
Bouchet et al. [7] had proposed the model which divides
the kidney into ﬁve parts in order to compute the absorbed
fractions of radiopharmaceuticals. In our study of dynamic
PET imaging, the inhomogeneity of kidney can also be seen.
Here,thekidneyisseparatedintotwoparts:parenchymaand
pelvis.Time-activitycurvesarepickedupfromeachpartand
are used to estimate the parameters. Though there are great
diﬀerences between each set of parameters, the output of the
model is basically in accord with the original curve.
2. MATERIALS AND METHOD
2.1. Subjects
Seven normal volunteers participated in the study. The age
o fv o l u n t e e r si sb e t w e e n3 4t o6 0y e a r s( m e a n± SD, 47 ± 11
years), the height is from 165 to 185cm (172 ± 7cm),and
the weight is from 53 to 94kg (76±12kg). None of them has
had a prior history of any major metabolic illnesses or renal











Figure 1: Model of kidney for FDG excretion.
volunteer. They were asked to fast for at least four hours and
to empty the bladder before the scanning. During the exper-
iment, they were asked to lie down still and to keep quiet.
Each volunteer was informed fully about the purposes and
procedures of the study and was asked to give a written con-
sent.
2.2. PETscanningprotocol
All the experiments were done with an ECAT EXACT HR+
PET (CTI/Siemens, Inc., TN, USA). The scanner provides 63
continuous transaxial slices with a 15.5cm ﬁeld of view. The
spatial resolution is 4.2mm full width at half maximum in
the centre ﬁeld of view. The experiments were performed in
a single bed position covering the kidneys. The tracer dose
of FDG, 4-5 mCi, was injected intravenously into the human
body, and PET scan began immediately after the injection. In
the sampling protocol, the dynamic imaging sequences con-
sisted of six 10-seconds frames; eight 20-seconds frames; six
30-seconds frames; ﬁve 60-seconds frames; four 300-seconds
frames; and three 600-seconds frames, which is in total of 32
frames for a total scan time of 61 minutes and 40 seconds.
2.3. Organtime-activitymeasurement
Kidney and abdominal aorta can be detected from the dy-
namic PET image. During study, the time-activity curve
was picked up from the drawn region of interest (ROI) in
each frame. The radioactivity was calculated by averaging
the whole voxel’s values within the ROI. Kidney is diﬀer-
ent from other organs, because it is heterogeneous for the
complex physiological function. Kidney is divided into two
parts: renal parenchyma and pelvis. In this study, the ROIs of
parenchymaandpelvisweredrawnforeachplanfromthe3D
image data in separate frames which have a best view of cer-
tain parts of the kidney. The ROI of parenchyma is drawn in
the frame for about 2 minutes after the scan, and the ROI of
pelvis is drawn in the frame for about 5 minutes. The blood
time-activity curve (BTAC) was derived from the ROI in ab-
dominal aorta [9], which is drawn in the frame for 1 minute.
2.4. Modelanalysis
A three-compartment model (Figure 1) with four parame-
ters is proposed to simply describe the excretion of FDG.
In this simple model, blood, renal parenchyma, and urine
compartments are assumed to be uniformly distributed with
FDG, respectively. The urine compartment includes urine in
the pelvis and urine in the bladder. For the high excretion of
FDG, the metabolism of FDG in kidney is unobvious and is
neglected in the model. k1 and k2 are the rate constants of
FDG between each compartment,
dC1
dt
= k1CB −k2C1,( 1 )
C1(t) = k1 · e−k2t ⊗CB(t), (2)
CT(t) = k1e−k2t ⊗ CB(t)+f1CB(t)+f2Cpelvis,( 3 )
where CB is the concentration of FDG in blood, C1 is the
concentration of FDG in parenchyma, C2 is the concentra-
tion of FDG in urine, Cpelvis is the concentration of FDG in
pelvis, and CT is the concentration of FDG detected from
PET. Equation (1) shows the kinetic description of the com-
partment model, (2)i sd e r i v e df r o m( 1), and (3) shows that
the activity in kidney detected by PET is not only decided
by C1, but also aﬀected by CB and Cpelvis. Kidney is an or-
gan which is rich in blood. So, the parameter f1 is used to
describe the eﬀect fraction from the blood to parenchyma.
Parenchyma and pelvis are so close to each other inside the
kidney that their eﬀect on each other cannot be neglected.
Thus, parameter f2 is introduced to calibrate the eﬀect of the




very high target-to-background ratio (Figure 2). Shreve et
al. [10] had used carbon-11-acetate as the tracer to detect
kidney. In their studies, no urinary tracer activity has ap-
peared in the intrarenal collecting system. Unlike carbon-
11-acetate and glucose, FDG is a kind of tracer which can-
not be reabsorbed when the initial urine passes through the
renal tubule. Thus, FDG can be detected in renal pelvis in
some frames. The concentration distribution variation can
be seen in kidney in diﬀerent frames. Figures 3(a) and 3(b)
are the same coronal sections of a dynamic PET study in one
frame (in 1 minute after injection), but the two images are
in diﬀerent brightness (window center) and contrast (win-
dow wide). The part of the kidney in which activity is highly
accumulated can be found by adjusting brightness and con-
trast (Figure 3(a)). Figure 2(b) gives the outline of the whole
organ in hot color scheme, and two images, Figures 3(a)
and 3(b) were fused. It can be seen from the fused image
(Figure 3(c)) that in early time after the injection, the FDG is
mostly accumulated in the edge of the kidney, where the re-
nal cortex and some of renal medulla are located. Figure 3(d)
is another fused image in frame for over 5 minutes after in-
jection. It can be seen that the high activity concentration
appears in the renal depression, where the position of renal
pelvis is.
3.2. Kineticparameter
Seven dynamic data sets from the seven subjects were used
for parameter estimation. The BTAC which has been picked
up from aorta and the tissue time-activity curve (TTAC) of













Figure 2: Some of the sequential transaxial images of one study.
(a) (b) (c) (d)
Figure 3: Images of kidney: (a)-(b) is one coronal section at 40–50seconds, (c) is the fused image of (a) and (b), and (d) is another fused
coronal section at 310–340seconds.




Subject1 3.4659 2.8042 0.15964 0.07574
Subject2 1.8423 2.3827 0.03293 0.10977
Subject3 1.3318 1.9806 0.19699 0.04073
Subject4 0.7703 0.8280 0.17543 0.03623
Subject5 1.5503 1.1120 0.10181 0.00000
Subject6 0.8981 0.9486 0.07342 0.04563
Subject7 1.2170 1.0007 0.03525 0.03525
Average 1.5822 1.5795 0.1269 0.0491
SD 0.9074 0.7981 0.0593 0.0347
of the parenchyma is the output of the model. Weighted
least squares principle [11] was used to ﬁt the simple kidney
model. The weight is the inverses of the measurement error.
Parameters for the model are listed in Table 1.
The average and standard deviations (SD) for k1, k2, f1,
and f2 arealsoshowninTable 1.Theaveragerateconstantk1
is 1.5822min−1,a n dk2 is 1.5795min−1. The eﬀect fraction
f1 is 0.1269, and f2 is 0.0491. The parameters of each subject
are compared with each other. Results show signiﬁcant dif-
ferences in the parameters for the subjects. Characters such
asage,height,orweightoftheindividualsubjectsmaybeone
of the reasons for the diﬀerences in the parameters. The con-
ﬁrmations of ROI for each study also lead to the huge diﬀer-
ences especially for f2, which describes the eﬀect from urine

































Figure 4: Time-activitycurve. Thenormallinerepresents thetime-
activity curve of renal parenchyma, the dashed line is the time-
activity curve of renal pelvis, and the asterisks show the point we
ﬁtted.
of pelvis to renal parenchyma. The further the ROI of the
parenchymaisfromthepelvis,thesmaller f2 willbe.Figure 4
shows the time-activity curve of one of the experiments. The
asterisk points are the result from compartment model and
estimated parameters.4 International Journal of Biomedical Imaging
4. DISCUSSION
The research of metabolism with FDG PET has been done
for many years, but only a little work is focused on kidney. In
some study, the function of kidney is just described by a con-
stant rate from plasma to urine [5]. For some tracer, kidney
can also be described by the classical three-compartment
model [12]. The kidney model for FDG is diﬀerent, because
F-18 FDG is excreted greatly into the tubular lumen and ac-
cumulatedintherenalcollectingsystem[8],noreabsorption
appears. So we use only one-direction compartment model
to describe kidney. Seven sets of dynamic clinical data were
being used to estimate the parameters. Results have shown
great diﬀerences in each subject. However, the output of the
model ﬁts well with the original curve from clinical data.
In order to make the model simple and workable, some
assumptionsweremadeinthisstudy:thebloodtime-activity
curve which was picked up from the aorta is used as plasma
time-activity curve in parameter estimation; no urine is ac-
cumulated in the parenchyma, and the eﬀect from the pelvis
is assumed to be consistent.
ThehighexcretionofFDGhasmadeitdiﬃculttoanalyze
theglucosemetabolismofkidneyandalsotodetectrenaldis-
eases. However, the high excretion of FDG can still provide
other important physiological information. In the dynamic
data, Parenchyma and pelvis can be distinguished, and the
time-activity curves are shown in Figure 4. The peaks of the
two curves which show the highest concentration appear at
diﬀerent time points. The peak of the pelvis appears a lit-
tle later than that of parenchyma. The result is in accord
with the renal physiology. Two peaks are shown in the time-
activity curve for pelvis. This can be explained by the phys-
iology of pelvis. Pelvis is the tissue which accumulates urine
temporarily. The urine is then transported to bladder. The
time-activity curve of the pelvis shows the process of urinary
transport to bladder. The process cannot just be described by
a rate constant. Hence, this model is just a preliminary study
of kidney, further investigation will be done.
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